Antibody–drug conjugates

descriptionPublicationkeyboard_double_arrow_right Article 28 Mar 2013 English Publisher:Springer Science and Business Media LLCJournal:Nature Reviews Drug Discovery, volume 12, pages 259-260 (issn: 1474-1776, eissn: 1474-1784,

Copyright policy )

Authors: Rachel S. Zolot; Satarupa Basu; Ryan P. Million;

doi: 10.1038/nrd3980

Antibody–drug conjugates

- Summary
- Metrics

Abstract

Antibody–drug conjugates (ADCs), which allow cytotoxic drugs to be selectively targeted to cancer cells, are attracting considerable interest. This article analyses the pipeline of ADCs, as well as trends in collaborations and deals related to ADC platforms.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	189
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%